Zyversa Therapeutics, Inc. ( (ZVSA) ) has released its Q3 earnings. Here is a breakdown of the information Zyversa Therapeutics, Inc. presented to its investors.
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for renal and inflammatory diseases. Operating in the biopharmaceutical sector, ZyVersa utilizes proprietary technologies to address high unmet medical needs in these areas.
In its third quarter of 2024, ZyVersa has announced progress in its clinical programs and financial results. The company is set to initiate a Phase 2a clinical trial for its Cholesterol Efflux Mediator VAR 200 in diabetic kidney disease in early 2025 and has formed a new scientific advisory board to guide its Inflammasome ASC Inhibitor IC 100 program aimed at obesity-related complications.
The company reported a net loss of approximately $2.4 million for the third quarter of 2024, which is an improvement from the previous year. ZyVersa has successfully raised $3.9 million during this period and expects further funding through various channels to meet its operational and clinical trial requirements. Research and development expenses saw a reduction, primarily due to decreased costs in manufacturing and clinical activities.
Looking ahead, ZyVersa is poised to initiate multiple studies for its IC 100 compound, with key trials scheduled to begin by the end of 2024. With a strategic focus on advancing its clinical pipeline, ZyVersa aims to achieve significant milestones that could potentially enhance shareholder value and meet the anticipated market demands in its specialized fields.
